Lilly's diabetes drug peglispro outperforms Lantus in 3 trials

05/13/2014 | Reuters

Data from several Phase III trials showed that Eli Lilly and Co.'s basal insulin peglispro was more effective than Sanofi's Lantus in lowering blood glucose levels among patients with type 2 diabetes, the company said. Lilly plans to submit the drug for regulatory review in the U.S. and Europe early next year.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Marlborough, MA
Test Technician
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT